Proteomics International Laboratories Ltd (ASX:PIQ) has engaged global life science company Abcam plc (LON:ABC) (OTCMKTS:ABCZF) to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test for the early detection of kidney disease in patients with type 2 diabetes.
Abcam is a leader in the supply of life science research tools and reagents, including supply to those companies developing and marketing diagnostic solutions around the world.
Under the terms of the commercial fee-for-service agreement, Abcam will produce the specialist reagents including synthetic protein standards and antibodies, required for the immunoassay version of the PromarkerD test.
According to the company, the engagement signifies Proteomics International achieving another milestone as it continues the path towards the commercialisation of PromarkerD in global markets
Commercialisation on track
Proteomics managing director Richard Lipscombe said by implementing these processes and securing an agreement with Abcam, the company’s commercialisation strategy aimed at delivering PromarkerD in global markets was on track.
He said: “Having recently achieved ISO 13485 registration for our organisation, which enables internationally certified manufacture of the PromarkerD immunoassay, we are now building our production capacity to meet the anticipated worldwide demand for the PromarkerD test.”
Framework for global roll-out
According to the company, working with Abcam will help streamline test production, allowing Proteomics International to service anticipated demand for PromarkerD worldwide.
The company has also completed the production of the relevant antibodies, which is expected to result in a stable, more consistent product over the long term, improve scale-up and help secure future supply chains.
Lipscombe said: “By engaging global manufacturing partners, such as Abcam who are experts in the manufacturing processes we require, we are building a robust framework that will help accelerate the worldwide roll-out of PromarkerD, and also facilitate the future commercialisation of our exciting pipeline of diagnostics under development.”
Headquartered in Cambridge, United Kingdom, Abcam is a global life sciences company focused on identifying, developing and distributing high-quality reagents.
Abcam operates across 13 locations around the world and has more than 1,600 employees serving customers in over 130 countries.